Skip to main content
Erschienen in: Targeted Oncology 6/2016

04.11.2016 | Meeting Report

Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7–11 October 2016

verfasst von: Martin Chopra

Erschienen in: Targeted Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Excerpt

The 2016 annual congress of the European Society for Medical Oncology (ESMO) in Copenhagen has broken records and was the largest ever oncology conference in Europe with just over 20,000 participants. There were over 1,640 studies presented at ESMO 2016, including 47 late breaking trials and over 1500 posters, and data totalling almost 100,000 patients in randomized trials was discussed at this conference. A record number of studies presented at ESMO 2016 were published on the day of their presentation in major medical journals. …
Literatur
1.
Zurück zum Zitat Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRefPubMed Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRefPubMed
2.
Zurück zum Zitat Turner NC, Ro J, Andre F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209–19.CrossRefPubMed Turner NC, Ro J, Andre F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209–19.CrossRefPubMed
3.
Zurück zum Zitat Hortobagyi GN. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Ann Oncol. 2016;27 (Supplement 6). LBA1_PR. Hortobagyi GN. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Ann Oncol. 2016;27 (Supplement 6). LBA1_PR.
4.
Zurück zum Zitat Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016.
5.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.CrossRefPubMed Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.CrossRefPubMed
6.
Zurück zum Zitat Eggermont AM. Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Ann Oncol. 2016, 27 (Supplement 6). LBA2_PR. Eggermont AM. Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Ann Oncol. 2016, 27 (Supplement 6). LBA2_PR.
7.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016.
8.
Zurück zum Zitat Mirza MR. A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Ann Oncol. 2016, 27 (Supplement 6). LBA3_PR. Mirza MR. A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Ann Oncol. 2016, 27 (Supplement 6). LBA3_PR.
9.
Zurück zum Zitat Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016.
10.
Zurück zum Zitat Langer CJ. Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Ann Oncol. 2016, 27 (Supplement 6). LBA46_PR. Langer CJ. Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Ann Oncol. 2016, 27 (Supplement 6). LBA46_PR.
11.
Zurück zum Zitat Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016.
12.
Zurück zum Zitat Reck M. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50 %. Ann Oncol. 2016, 27 (Supplement 6). LBA8_PR. Reck M. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50 %. Ann Oncol. 2016, 27 (Supplement 6). LBA8_PR.
13.
Zurück zum Zitat Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016.
14.
Zurück zum Zitat Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMed Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMed
15.
Zurück zum Zitat Barlesi F. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2 L/3L NSCLC. Ann Oncol. 2016, 27 (Supplement 6). LBA44_PR. Barlesi F. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2 L/3L NSCLC. Ann Oncol. 2016, 27 (Supplement 6). LBA44_PR.
16.
17.
Zurück zum Zitat Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.CrossRefPubMed Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.CrossRefPubMed
18.
Zurück zum Zitat Choueiri TK. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Ann Oncol. 2016, 27 (Supplement 6). LBA30_PR. Choueiri TK. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Ann Oncol. 2016, 27 (Supplement 6). LBA30_PR.
Metadaten
Titel
Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7–11 October 2016
verfasst von
Martin Chopra
Publikationsdatum
04.11.2016
Verlag
Springer International Publishing
Erschienen in
Targeted Oncology / Ausgabe 6/2016
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-016-0464-3

Weitere Artikel der Ausgabe 6/2016

Targeted Oncology 6/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.